The Department of Health and Social Care issued a press release announcing that a second oral antiviral treatment, Paxlovid, has been included in the Panoramic trial, a national study run by the University of Oxford helping immunosuppressed people suffering from Covid-19.
Paxlovid reduced the risk of hospitalisation or death by 88% in clinical trials and is already available directly through the NHS to highest-risk patients
In just over 3 months, more than 20,000 patients have joined the nationwide study to help generate vital data on Molnupiravir, the first oral antiviral to be made available.
Paxlovid is expected to benefit 17,500 vulnerable patients in the UK over the next few months.
The Panoramic study is open to adults over the age of 50 or those aged 18 to 49 with an underlying health condition that can increase the risk of developing severe Covid-19, who have received a positive Covid-19 test result, and who are experiencing symptoms that started in the previous 5 days.
